Pheon Hopes To Stir Up ADC Space With First-In-Class Compound
Launches With $68m Series A
The UK firm with a presence in Boston has just emerged but Pheon’s CEO Bertrand Damour tells Scrip that big pharma is already showing interest in its next-generation antibody-drug conjugate.
You may also be interested in...
The Swedish rare disease specialist has expanded its hematology franchise by getting the European rights to ADC Therapeutics’ Zynlonta, which has yet to make much impact commercially in the US.
Following in the wake of Merck & Co's acquisition of VelosBio, the German major is spending big to get hold of the Swiss oncology biotech NBE-Therapeutics which is also targeting the ROR1 protein.
Mads Krogsgaard Thomsen, CEO of the Novo Nordisk Foundation and the man who supervised the development of , describes the unprecedented growth of the obesity market and what might come next for Novo.